Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 3/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.51 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.47 |
| ▸ | CCNC | P24863 | 4/20 | 0.46 |
| ▸ | CDK8 | P49336 | 4/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18085954 | 0.82 | SCD (0.65) | SCDROCK2SCD5ADAM17 | |
| SCHEMBL3217208 | 0.82 | NAMPT (0.55) | ROCK2SCD5 | |
| SCHEMBL16565652 | 0.80 | SCD (0.60) | SCDROCK2SCD5ADAM17 | |
| SCHEMBL165005 | 0.77 | SCD (0.55) | SCDROCK2SCD5 | |
| SCHEMBL2038614 | 0.75 | TSHR (0.50) | ROCK2 | |
| SCHEMBL17437291 | 0.73 | SCD (0.53) | SCDROCK2SCD5CCNCCDK8 | |
| SCHEMBL17437292 | 0.73 | SCD (0.53) | SCDROCK2SCD5CCNCCDK8 | |
| SCHEMBL13212081 | 0.73 | ROCK2 (0.55) | SCDROCK2CCNCCDK8GRM5 | |
| SCHEMBL12459923 | 0.73 | HSD11B1 (0.50) | SCDROCK2CCNCCDK8JAK2 | |
| SCHEMBL19226714 | 0.72 | KMT2A (0.53) | SCDROCK2CCNCCDK8GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | SCD 3224/4885ROCK2 846/4885SCD5 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.